- Home
- TCRT
as 04-02-2025 4:00pm EST
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 2.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 946.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.31 - $18.50 | Next Earning Date: | 05-14-2025 |
| Revenue: | $10,000 | Revenue Growth: | 100.00% |
| Revenue Growth (this year): | 5680500% | Revenue Growth (next year): | N/A |
Latest Alaunos Therapeutics Inc. News
TCRT Breaking Stock News: Dive into TCRT Ticker-Specific Updates for Smart Investing
TipRanks
6 months ago
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy
The Telegraph
10 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
10 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
10 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
10 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
10 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Simply Wall St.
10 months ago
Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
Simply Wall St.
10 months ago
Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Compare TCRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCRT Alaunos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.